title: Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment.
abstract: BACKGROUND
  Prenatal serotonin reuptake inhibitor (SRI) exposure has been related to adverse newborn neurobehavioral outcomes; however, these effects have not been compared to those that may arise from prenatal exposure to maternal major depressive disorder (MDD) without SRI treatment. This study examined potential effects of MDD with and without SRI treatment on newborn neurobehavior.
  
  
  METHODS
  This was a prospective, naturalistic study. Women were seen at an outpatient research center twice during pregnancy (26-28 and 36-38 weeks gestational age (GA)). Psychiatric diagnoses were assessed using the Structured Clinical Interview for the DSM-IV; medication use was measured with the Timeline Follow-Back instrument. Three groups were established based upon MDD diagnosis and SRI use: Control (N = 56), MDD (N = 20), or MDD + SRI (N = 36). Infants were assessed on a single occasion within 3 weeks of birth with the NICU Network Neurobehavioral Assessment Scale. Generalized Linear Modeling was used to examine neurobehavioral outcomes by exposure group and infant age at assessment.
  
  
  RESULTS
  Full-term infants exposed to MDD + SRIs had a lower GA than CON or MDD-exposed infants and, controlling for GA, had lower quality of movement and more central nervous system stress signs. In contrast, MDD-exposed infants had the highest quality of movement scores while having lower attention scores than CON and MDD + SRI-exposed infants.
  
  
  CONCLUSIONS
  MDD + SRI-exposed infants seem to have a different neurobehavioral profile than MDD-exposed infants in the first 3 weeks after delivery; both groups may have different neurobehavioral profiles with increasing age from birth.
authors: Department of Pediatrics, Brown Center for the Study of Children at Risk, Women and Infants Hospital of Rhode Island and the Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, Rhode Island 02905, USA. Amy_Salisbury@brown.edu
authors: Amy L
authors: AL
authors: Salisbury
authors: Katherine L
authors: KL
authors: Wisner
authors: Teri
authors: T
authors: Pearlstein
authors: Cynthia L
authors: CL
authors: Battle
authors: Laura
authors: L
authors: Stroud
authors: Barry M
authors: BM
authors: Lester
mesh_terms: D000328:Adult; D003865:Major Depressive Disorder / Q000150:complications* / Q000188:drug therapy; D005260:Female; D005865:Gestational Age; D006801:Humans; D018730:Infant Behavior / Q000187:drug effects* / Q000523:psychology; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000139:chemically induced*; D009483:Neuropsychological Tests; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000523:psychology*; D011446:Prospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors